FONDE: Novo Nordisk har blandt andet spenderet på forskning i leversygdom og i kræftcellers svagheder. Syddansk Universitet ...

Ny national indgang til sundhedsdata skal styrke dansk sundhedsforskning og bane vej for nye sundhedsløsninger. Indtil nu har sundhedsdata ligget spredt i det danske sundhedsvæsen og med begrænsede mu ...

Novo-aktiens stigning er et lille plaster på såret efter en voldsom periode, vurderer TV 2s erhvervsanalytiker.

Novo Nordisk has invested 6.4bn Brazilian reais ($1.09bn) to expand its facility in Brazil as the company ramps up efforts to increase production of its flagship glucagon-like peptide 1 receptor ...

In this exclusive interview, Business Today speaks with Vikrant Shrotriya, Managing Director of Novo Nordisk India, about the significance of semaglutide (the active ingredient in Wegovy), its ...

As a pioneer in diabetes care, Novo Nordisk NVO claims 34% of the USD 80 billion-plus diabetes treatment market and roughly half of the insulin market, itself worth more than USD 15 billion.

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire across the globe and make inroads into large markets like Brazil.

Novo Nordisk A/S has a fifty-two week low of $60.61 and a fifty-two week high of $148.15. The company has a market capitalization of $285.03 billion, a price-to-earnings ratio of 19.31, a P/E/G ...

Novo Nordisk A/S Stock Performance Shares of NYSE NVO opened at $63.52 on Tuesday. The stock’s 50-day moving average is $80.37 and its 200 day moving average is $95.75. The stock has a market ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 billion) in Brazil to increase production at its facility in Minas Gerais.